Cargando…
Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system and mainly affects young adults. Its natural history has changed in recent years with the advent of disease-modifying drugs, which have been available since the early 1990s. The increasing number of first-line a...
Autores principales: | Lugaresi, Alessandra, di Ioia, Maria, Travaglini, Daniela, Pietrolongo, Erika, Pucci, Eugenio, Onofrj, Marco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699254/ https://www.ncbi.nlm.nih.gov/pubmed/23836975 http://dx.doi.org/10.2147/NDT.S45144 |
Ejemplares similares
-
Relation between Pro-inflammatory Cytokines and Acetylcholine Levels in Relapsing-Remitting Multiple Sclerosis Patients
por: Reale, Marcella, et al.
Publicado: (2012) -
Circadian Activity Rhythm in Early Relapsing–Remitting Multiple Sclerosis
por: Tonetti, Lorenzo, et al.
Publicado: (2019) -
Data of safety in a single-center alemtuzumab treated population
por: di Ioia, Maria, et al.
Publicado: (2020) -
Postural Control in Relapsing-Remitting Multiple Sclerosis
por: Cusin, Flavia Salvaterra, et al.
Publicado: (2022) -
Risk knowledge of people with relapsing-remitting multiple sclerosis – Results of an international survey
por: Giordano, Andrea, et al.
Publicado: (2018)